Xavier Estivill

Xavier Estivill

Auto-generated profile, based on publicly available information

Xavier Estivill

Genomics and Disease Group, Bioinformatics and Genomics Programme, Centre for Genomic Regulation (CRG), Barcelona, Catalonia, Spain

Research Focus & Metrics

Academic Career Length

44Years (1983-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 November 2006 in Nature
Verified
Journal Article
Closed access
PDF file
RRRichard Redon
Richard Redon
SIShumpei Ishikawa
Shumpei Ishikawa
KFKaren R. Fitch
Karen R. Fitch
LFLars Feuk
Lars Feuk
GPGeorge H. Perry
George H. Perry
MHMatthew E. Hurles
Matthew E. Hurles

15 September 2013 in Nature
Verified
Journal Article
Open access
PDF file
TCThe Geuvadis Consortium
The Geuvadis Consortium
TLTuuli Lappalainen
Tuuli Lappalainen
MSMichael Sammeth
Michael Sammeth
MFMarc Friedländer
Marc Friedländer
PHPeter A. C. ‘t Hoen
Peter A. C. ‘t Hoen
EDEmmanouil T. Dermitzakis
Emmanouil T. Dermitzakis
Genome sequencing projects are discovering millions of genetic variants in humans, and interpretation of their functional effects is essential for understanding the genetic basis of variation in human traits. Here we report sequencing and deep analysis of messenger RNA and microRNA from lymphoblastoid cell lines of 462 individuals from the 1000 Genomes Project—the first uniformly processed high-throughput RNA-sequencing data from multiple human populations with high-quality genome sequences. We discover extremely widespread genetic variation affecting the regulation of most genes, with transcript structure and expression level variation being equally common but genetically largely independent. Our characterization of causal regulatory variation sheds light on the cellular mechanisms of regulatory and loss-of-function variation, and allows us to infer putative causal variants for dozens of disease-associated loci. Altogether, this study provides a deep understanding of the cellular mechanisms of transcriptome variation and of the landscape of functional variants in the human genome.

5 June 2011 in Nature
Verified
Journal Article
Open access
PDF file
XPXose S. Puente
Xose S. Puente
MPMagda Pinyol
Magda Pinyol
VQVíctor Quesada
Víctor Quesada
LCLaura Conde
Laura Conde
GOGonzalo R. Ordóñez
Gonzalo R. Ordóñez
ECElías Campo
Elías Campo
Analysis of the genomes of four patients with chronic lymphocytic leukaemia, and validation in more than 300 patients, has identified four genes — NOTCH1, MYD88, XPO1 and KLHL6 — that are recurrently mutated in the condition. Mutations in NOTCH1, MYD88 and XPO1 are thought to contribute to the clinical evolution of the disease. Evidence that NOTCH1 and MYD88 mutations are activating events highlights them as potential therapeutic targets. Chronic lymphocytic leukaemia (CLL), the most frequent leukaemia in adults in Western countries, is a heterogeneous disease with variable clinical presentation and evolution1,2. Two major molecular subtypes can be distinguished, characterized respectively by a high or low number of somatic hypermutations in the variable region of immunoglobulin genes3,4. The molecular changes leading to the pathogenesis of the disease are still poorly understood. Here we performed whole-genome sequencing of four cases of CLL and identified 46 somatic mutations that potentially affect gene function. Further analysis of these mutations in 363 patients with CLL identified four genes that are recurrently mutated: notch 1 (NOTCH1), exportin 1 (XPO1), myeloid differentiation primary response gene 88 (MYD88) and kelch-like 6 (KLHL6). Mutations in MYD88 and KLHL6 are predominant in cases of CLL with mutated immunoglobulin genes, whereas NOTCH1 and XPO1 mutations are mainly detected in patients with unmutated immunoglobulins. The patterns of somatic mutation, supported by functional and clinical analyses, strongly indicate that the recurrent NOTCH1, MYD88 and XPO1 mutations are oncogenic changes that contribute to the clinical evolution of the disease. To our knowledge, this is the first comprehensive analysis of CLL combining whole-genome sequencing with clinical characteristics and clinical outcomes. It highlights the usefulness of this approach for the identification of clinically relevant mutations in cancer.

15 July 2019 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
AIAnorexia Nervosa Genetics Initiative
Anorexia Nervosa Genetics Initiative
HWHunna J. Watson
Hunna J. Watson
ECEating Disorders Working Group of the Psychiatric Genomics Consortium
Eating Disorders Working Group of the Psychiatric Genomics Consortium
ZYZeynep Yilmaz
Zeynep Yilmaz
LTLaura M. Thornton
Laura M. Thornton
CBCynthia Bulik
Cynthia Bulik

11 November 2012 in Nature Genetics
Verified
Journal Article
Open access
PDF file
LTLam Tsoi
Lam Tsoi
SSSarah L Spain
Sarah L Spain
JKJo Knight
Jo Knight
EEEva Ellinghaus
Eva Ellinghaus
PSPhilip E Stuart
Philip E Stuart
RTRichard C Trembath
Richard C Trembath
Richard Trembath and colleagues report a meta-analysis of genome-wide association studies for psoriasis, including 2 cohorts genotyped on the custom Immunochip array, in a total of 10,588 cases and 22,806 controls. They identify 15 new susceptibility loci and refine signals in previously known loci, highlighting a role for innate host defense in susceptibility to psoriasis. To gain further insight into the genetic architecture of psoriasis, we conducted a meta-analysis of 3 genome-wide association studies (GWAS) and 2 independent data sets genotyped on the Immunochip, including 10,588 cases and 22,806 controls. We identified 15 new susceptibility loci, increasing to 36 the number associated with psoriasis in European individuals. We also identified, using conditional analyses, five independent signals within previously known loci. The newly identified loci shared with other autoimmune diseases include candidate genes with roles in regulating T-cell function (such as RUNX3, TAGAP and STAT3). Notably, they included candidate genes whose products are involved in innate host defense, including interferon-mediated antiviral responses (DDX58), macrophage activation (ZC3H12C) and nuclear factor (NF)-κB signaling (CARD14 and CARM1). These results portend a better understanding of shared and distinctive genetic determinants of immune-mediated inflammatory disorders and emphasize the importance of the skin in innate and acquired host defense.

11 December 2011 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
VQVíctor Quesada
Víctor Quesada
LCLaura Conde
Laura Conde
NVNeus Villamor
Neus Villamor
GOGonzalo R Ordóñez
Gonzalo R Ordóñez
PJPedro Jares
Pedro Jares
CLCarlos López-Otín
Carlos López-Otín